Biotech Values

[DewDiligence]

PTLA—If a SoC VTE patient gets 14 days Lovenox and then 15 days oral (because injections are difficult at home), then it doesn't seem unreasonable to test that sequential-drug SoC against a single drug [Betrixaban] with a potentially lower rate of bleeds.

But that’s not what PTLA is doing in the phase-3 trial!! Instead, PTLA is testing 35 days of Betrixaban against 6-14 days of Lovenox followed by 21-29 days of placebo.